RAB10: An alzheimer’s disease resilience locus and potential drug target

Justina P. Tavana, Matthew Rosene, Nick O. Jensen, Perry G. Ridge, John S.K. Kauwe, Celeste M. Karch

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3′-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalClinical Interventions in Aging
Volume14
DOIs
StatePublished - Jan 1 2019

Keywords

  • Alzheimer’s disease
  • App
  • Gtpase
  • Rab10
  • Resilience
  • Retromer

Fingerprint Dive into the research topics of 'RAB10: An alzheimer’s disease resilience locus and potential drug target'. Together they form a unique fingerprint.

  • Cite this